Bausch Health Cos (NYSE:BHC) Price Target Raised to $10.00

01 Nov 2026, 01:48 by Doug Wharley · The Cerbat Gem

Bausch Health Cos (NYSE:BHC – Free Report) had its price objective lifted by Royal Bank Of Canada from $9.00 to $10.00 in a research report report published on Thursday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

BHC has been the topic of several other research reports. Weiss Ratings raised Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Finally, Zacks Research raised Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bausch Health Cos currently has a consensus rating of “Hold” and an average price target of $8.25.

Check Out Our Latest Research Report on Bausch Health Cos

Bausch Health Cos Stock Down 7.8%

NYSE:BHC opened at $8.22 on Thursday. The firm has a market cap of $3.08 billion, a PE ratio of -3.59 and a beta of 0.37. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $9.04. The company’s 50-day moving average price is $6.23 and its two-hundred day moving average price is $5.72.

Bausch Health Cos (NYSE:BHC – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.52. The business had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Bausch Health Cos had a negative return on equity of 369.48% and a negative net margin of 7.57%. On average, research analysts expect that Bausch Health Cos will post 4.35 EPS for the current fiscal year.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the sale, the insider owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Institutional Trading of Bausch Health Cos

Several institutional investors and hedge funds have recently made changes to their positions in the business. Paulson & CO. Inc. acquired a new position in shares of Bausch Health Cos during the 2nd quarter worth about $361,151,000. The Manufacturers Life Insurance Company bought a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $1,167,000. Dimensional Fund Advisors LP increased its stake in shares of Bausch Health Cos by 10.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after acquiring an additional 350,823 shares during the last quarter. MFN Partners Management LP bought a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $29,580,000. Finally, Bank of America Corp DE acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at approximately $2,816,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos News Roundup

Here are the key news stories impacting Bausch Health Cos this week:

Positive Sentiment: Raised 2026 revenue outlook: Bausch Health now expects fiscal 2026 revenue of $11.0 billion to $11.2 billion, above the approximately $10.9 billion analyst consensus. This signals confidence in continued operating momentum.
Positive Sentiment: Third-quarter earnings beat expectations: The company reported $1.77 in quarterly EPS versus consensus estimates ranging from $1.08 to $1.25, while revenue reached approximately $2.90 billion to $2.94 billion, ahead of expectations. Growth in the Salix business, led by Xifaxan, and improved profitability were key drivers. BHC Q3 earnings beat article
Positive Sentiment: Debt-management action: Bausch Health Americas plans to redeem $643 million of 8.5% notes due in 2027. Redeeming high-cost debt could reduce future interest expense and refinancing risk. Debt redemption article
Positive Sentiment: Higher price target: Royal Bank of Canada raised its BHC target to $10 from $9, although it maintained a “sector perform” rating.
Neutral Sentiment: Analyst views remain divided: Conflicting opinions on Bausch Health suggest that strong results have not eliminated concerns about valuation, debt, and the durability of growth. Analyst views article
Neutral Sentiment: Options activity increased: Investors purchased roughly 6,018 call options, about 120% above typical volume, indicating heightened speculative interest but not necessarily sustained fundamental demand.
Negative Sentiment: Profit-taking and underlying risks: After the stock’s sharp post-earnings advance, investors may be locking in gains. Bausch Health continues to report a negative net margin and negative return on equity, leaving leverage and execution risks as important concerns.

About Bausch Health Cos

(Get Free Report)

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.